Company intelligence / Profile preview

Beijing Genova Biotech

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Novaferon (interferon alpha/beta receptor fusion protein) is approved in China for hepatitis B and has demonstrated antiviral and immunomodulatory potency. Nova-EPO and Nova-GM-CSF are in preclinical stages. The company has additional programs for metabolic/endocrine diseases, including biosimilars for insulin and growth hormone heading into or recently completed EU trials.

Therapeutic areas: Infectious DiseasesOncologyHematologyEndocrinology
Modalities: Recombinant proteinFusion proteinCytokineColony-stimulating factor
Industry: Biotech

Drug pipeline

2 assets

Nova-GM-CSF

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

CDMO service partnerships for nucleic acid vaccine manufacturingCollaborations with EU/EMA for biosimilar trials

Beyond the preview

Go deeper on Beijing Genova Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Genova Biotech.

Explore the full profile